BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China · Delayed Price · Currency is CNY

32.94

+1.11 (3.49%)

At close: Jul 31, 2026

-67.06% (1Y)

Market Cap	14.34B -66.1%
Revenue (ttm)	1.30B +9.1%
Net Income	50.85M -63.2%
EPS	0.12 -63.7%
Shares Out	435.23M
PE Ratio	276.95
Forward PE	n/a
Dividend	0.02 (0.05%)
Ex-Dividend Date	Jun 9, 2026

Volume	15,331,529
Open	31.41
Previous Close	31.83
Day's Range	31.41 - 33.86
52-Week Range	28.74 - 122.59
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, inc... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 1,196

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688166

Full Company Profile

Financial Performance

In 2025, SHA:688166's revenue was 1.22 billion, a decrease of -4.59% compared to the previous year's 1.28 billion. Earnings were 54.51 million, a decrease of -71.18%.

Financial Statements